DOCSLIB.ORG

Article Reverse Phenotyping After Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Article Reverse Phenotyping After Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome Article Reverse Phenotyping after Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome Samuela Landini,1,2,3 Benedetta Mazzinghi ,4 Francesca Becherucci ,4 Marco Allinovi,2,3 Aldesia Provenzano ,1,3 Viviana Palazzo,1 Fiammetta Ravaglia,4 Rosangela Artuso ,1 Emanuele Bosi ,2 Stefano Stagi ,5 Giulia Sansavini,4 Francesco Guzzi ,2,3,4 Luigi Cirillo ,4 Augusto Vaglio ,2,3,4 Luisa Murer ,6 Licia Peruzzi ,7 Andrea Pasini ,8 Marco Materassi,4 Rosa Maria Roperto,4 Hans-Joachim Anders ,9 Mario Rotondi ,10 Sabrina Rita Giglio ,1,2,3 and Paola Romagnani 2,3,4 Due to the number of contributing authors, Abstract the affiliations are Background and objectives Nephrotic syndrome is a typical presentation of genetic podocytopathies but listed at the end of occasionally other genetic nephropathies can present as clinically indistinguishable phenocopies. We hypoth- this article. esized that extended genetic testing followed by reverse phenotyping would increase the diagnostic rate for these Correspondence: patients. Prof. Paola Romagnani or Prof. Design, setting, participants, & measurements All patients diagnosed with nephrotic syndrome and referred to our Sabrina Giglio, center between 2000 and 2018 were assessed in this retrospective study. When indicated, whole-exome sequencing Department of fi Clinical and and in silico ltering of 298 genes related to CKD were combined with subsequent reverse phenotyping in patients Experimental and families. Pathogenic variants were defined according to current guidelines of the American College of Medical Biomedical Sciences Genetics. “Mario Serio”, University of Results A total of 111 patients (64 steroid-resistant and 47 steroid-sensitive) were included in the study. Not a Florence, Viale Pieraccini 6, 50139, single pathogenic variant was detected in the steroid-sensitive group. Overall, 30% (19 out of 64) of steroid- Florence, Italy. resistant patients had pathogenic variants in podocytopathy genes, whereas a substantial number of variants E-mail:paola. were identified in other genes, not commonly associated with isolated nephrotic syndrome. Reverse romagnani@unifi.it or phenotyping, on the basis of a personalized diagnostic workflow, permitted to identify previously unrecognized sabrina.giglio@ meyer.it clinical signs of an unexpected underlying genetic nephropathy in a further 28% (18 out of 64) of patients. These patients showed similar multidrug resistance, but different long-term outcome, when compared with genetic podocytopathies. Conclusions Reverse phenotyping increased the diagnostic accuracy in patients referred with the diagnosis of steroid-resistant nephrotic syndrome. CJASN 15: 89–100, 2020. doi: https://doi.org/10.2215/CJN.06060519 Introduction nephropathies outside the podocytopathy spectrum Isolated nephrotic syndrome is classified, according (e.g., Alport syndrome, Dent disease, or Fabry to the response to steroids, as steroid-sensitive or disease) are usually recognized upon standard diag- steroid-resistant nephrotic syndrome (1,2). Although nostic work-up. However, steroid-resistant nephrotic steroid-sensitive nephrotic syndrome usually has a syndrome can rarely be the only evident clinical sign, favorable prognosis, steroid-resistant nephrotic at disease onset or even later (14–18). When this syndrome can progress to ESKD (3–7). Indeed, happens, these genetic nephropathies are often mis- despite some patients’ response to immunosuppres- classified and treated as isolated steroid-resistant sion in terms of proteinuria reduction, many are nephrotic syndrome when genetic testing for com- multidrug resistant (6). Genetic testing using ex- monly reported disease-causing genes (i.e., podocyt- tended panels of podocytopathy genes has become a opathy genes) proves to be negative. These conditions valuable diagnostic tool to identify monogenic are referred to as phenocopies of monogenic podocyto- podocytopathies, which account for about 30% of pathies (19–25). A phenocopy is defined as “a pheno- patients affected by steroid-resistant nephrotic syn- typic trait or disease that resembles the trait expressed drome (5,8–12). In addition, a recent report sugges- by a particular genotype, but in an individual who is ted that steroid-sensitive nephrotic syndrome may not a carrier of that genotype” (26). Recently, by also occasionally be of genetic origin (13). All other applying whole-exome sequencing, Warejko et al.(27) cases of isolated nephrotic syndrome are usually reported the diagnosis of a phenocopy in 5% of patients assumed to be of nongenetic cause. Genetic with steroid-resistant nephrotic syndrome. We www.cjasn.org Vol 15 January, 2020 Copyright © 2020 by the American Society of Nephrology 89 90 CJASN 252 patients diagnosed with nephrotic syndrome and referred to our center between January 2000 and December 2018 47 patients presenting with: - clinical, laboratory or biopsy signs of an immune-mediated disease, n=17 - macroscopic hematuria, predominant tubular proteinuria, n=2 - syndromic nephrotic syndrome and/or extra-renal involvement, n=4 - known family history of nephrotic syndrome, n=10 - parents DNA untraceable, n=14 205 evaluated patients 141 steroid-sensitive nephrotic syndrome 94 patients affected by unfrequently relapsing and not steroid-dependent nephrotic syndrome 64 47 steroid-resistant steroid-sensitive nephrotic syndrome nephrotic syndrome 111 patients sent to genetic analysis Figure 1. | Flowchart for the selection of 111 patients included in the study. hypothesized that establishing standardized criteria to define nephrologists and from medical records. Inclusion criteria podocytopathy versus phenocopy genes, and adding re-eval- were onset of symptoms before 30 years of age and a uation of patients and their family (i.e., “reverse phenotyp- clinical diagnosis of nephrotic syndrome (e.g.,nephrotic ing”) after genetic testing, could correctly segregate the range proteinuria, hypoalbuminemia, edema) or nephrotic identified genetic variants to previously unrecognized range proteinuria with kidney histology of FSGS, minimal clinical symptoms and increase the sensitivity of the genetic change disease, or diffuse mesangial sclerosis. Exclusion analysis. criteria were (1) evidence of clinical, laboratory, or kidney biopsy signs of an immune-mediated disease; (2)macro- scopic hematuria or predominantly tubular proteinuria Materials and Methods (low-molecular-weight proteins .50% according to urine Patients protein electrophoresis) (28); (3) syndromic nephrotic syn- All consecutive patients diagnosed with nephrotic syn- drome and/or presence of extrarenal signs or symptoms drome and referred to the Nephrology Unit of the Meyer (e.g., sensorineural hearing loss, ocular abnormalities); (4) Children’s University Hospital of Florence from January known family history of nephrotic syndrome; and (5) 2000 to December 2018 were assessed for inclusion in this untraceable parents’ DNA (Figure 1). The remaining pa- retrospective study (Figure 1, Supplemental Table 1). tients were then subclassified in steroid-resistant or steroid- Participants were followed from the day of referral until sensitive nephrotic syndrome. The majority of patients 31 December 2018, with no loss to follow-up. Demographic, with steroid-resistant nephrotic syndrome were diagnosed clinical, and laboratory data were retrospectively collected in another nephrology center and subsequently referred to from direct interview of patients, families, and referring our hospital, therefore detailed laboratory information at CJASN 15: 89–100, January, 2020 Reverse Phenotyping in Nephrotic Syndrome, Landini et al. 91 disease onset was not always available. Those affected count approach as detailed in Supplemental Appendix 1. by congenital nephrotic syndrome, or with a histologic Synonymous variants and intronic variants that were not diagnosis of diffuse mesangial sclerosis, or advanced kidney located within splice site regions were excluded. Vari- failure at diagnosis were considered comparable with ants were confirmed in the patients’ and families’ DNA patients who were steroid-resistant, although not treated by Sanger sequencing. with steroids. Among patients who were steroid-sensitive, only frequently relapsing or steroid-dependent patients Definition of Podocytopathy and Phenocopy Genes were selected for genetic testing and inclusion in the study. We systematically defined podocytopathy versus phe- First-degree relatives were either included before the study nocopy genes on the basis of Online Mendelian Inheri- fi or asked to participate after the identi cation of potentially tance in Man (OMIM; https://www.omim.org). causative gene variants in the patient. The local Ethics Accordingly, genes identified in OMIM as causing “ne- ’ Committee of the Meyer Children s University Hospital of phrotic syndrome” or “FSGS” were considered “podo- Florence approved the study. The study was conducted cytopathy genes.” In contrast, genes identified in OMIM according to the Declaration of Helsinki. A clinical geneticist to cause a syndromic disorder, with nephrotic syndrome counseled all patients and their families regarding the beingonlyoneamongmanyotherclinicalsignsoreven whole-exome sequencing procedure, and all participants not mentioned at all, were considered “phenocopy genes.” or their legal guardians gave written informed consent. Recently published literature indicating a causative path- ogenic role for a gene in nephrotic syndrome was also Sequencing and Bioinformatic Analysis considered to stratify cases as podocytopathy versus pheno-
Load more

Recommended publications
  • HPSE2 Gene Heparanase 2 (Inactive)
    HPSE2 gene heparanase 2 (inactive) Normal Function The HPSE2 gene provides instructions for making a protein called heparanase 2. Little is known about this protein, but its structure is similar to that of another protein called heparanase 1. Heparanase 1 is an enzyme that splits (cleaves) molecules called heparan sulfate proteoglycans (HSPGs) by removing the heparan sulfate portion (the side chain). HSPGs are important parts of the lattice of proteins and other molecules outside the cell (extracellular matrix) and of basement membranes, which are thin, sheet-like structures that separate and support cells in many tissues. Cleavage of HSPGs by heparanase 1 may lead to changes in the basement membrane or extracellular matrix that allow cell movement or release of substances from the cell. The specific function of the heparanase 2 enzyme is not well understood, but studies suggest that it may block the action of heparanase 1. Health Conditions Related to Genetic Changes Migraine MedlinePlus Genetics provides information about Migraine Ochoa syndrome At least nine HPSE2 gene mutations have been identified in people with Ochoa syndrome (also called urofacial syndrome), a disorder that causes urinary problems and unusual facial expressions. These mutations result in changes in the heparanase 2 protein that likely prevent it from functioning. The connection between HPSE2 gene mutations and the features of Ochoa syndrome are unclear. Because the areas of the brain that control facial expression and urination are in close proximity, some researchers have suggested that the genetic changes may lead to an abnormality in this brain region that may account for the symptoms of Ochoa syndrome.
    [Show full text]
  • Diagnosing Platelet Secretion Disorders: Examples Cases
    Diagnosing platelet secretion disorders: examples cases Martina Daly Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Disclosures for Martina Daly In compliance with COI policy, ISTH requires the following disclosures to the session audience: Research Support/P.I. No relevant conflicts of interest to declare Employee No relevant conflicts of interest to declare Consultant No relevant conflicts of interest to declare Major Stockholder No relevant conflicts of interest to declare Speakers Bureau No relevant conflicts of interest to declare Honoraria No relevant conflicts of interest to declare Scientific Advisory No relevant conflicts of interest to declare Board Platelet granule release Agonists (FIIa, Collagen, ADP) Signals Activation Shape change Membrane fusion Release of granule contents Platelet storage organelles lysosomes a granules Enzymes including cathepsins Adhesive proteins acid hydrolases Clotting factors and their inhibitors Fibrinolytic factors and their inhibitors Proteases and antiproteases Growth and mitogenic factors Chemokines, cytokines Anti-microbial proteins Membrane glycoproteins dense (d) granules ADP/ATP Serotonin histamine inorganic polyphosphate Platelet a-granule contents Type Prominent components Membrane glycoproteins GPIb, aIIbb3, GPVI Clotting factors VWF, FV, FXI, FII, Fibrinogen, HMWK, FXIII? Clotting inhibitors TFPI, protein S, protease nexin-2 Fibrinolysis components PAI-1, TAFI, a2-antiplasmin, plasminogen, uPA Other protease inhibitors a1-antitrypsin, a2-macroglobulin
    [Show full text]
  • Urinary Tract Effects of HPSE2 Mutations
    BRIEF COMMUNICATION www.jasn.org Urinary Tract Effects of HPSE2 Mutations † Helen M. Stuart,* Neil A. Roberts,* Emma N. Hilton,* Edward A. McKenzie, Sarah B. Daly,* † ‡ Kristen D. Hadfield,* Jeffery S. Rahal,* Natalie J. Gardiner, Simon W. Tanley, | Malcolm A. Lewis,* Emily Sites,§ Brad Angle,§ Cláudia Alves, Teresa Lourenço,¶ Márcia Rodrigues,¶ Angelina Calado,** Marta Amado,** Nancy Guerreiro,** Inês Serras,** †† †† || Christian Beetz , Rita-Eva Varga , Mesrur Selcuk Silay,§§ John M. Darlow, ¶¶ || || ††† Mark G. Dobson , ¶¶ David E. Barton , *** Manuela Hunziker,¶¶ Prem Puri,¶¶*** ‡‡‡ Sally A. Feather, Judith A. Goodship ,§§§ Timothy H.J. Goodship ,§§§ Heather J. ||| BRIEF COMMUNICATION Lambert ,§§§ Heather J. Cordell ,§§§ the UK VUR Study Group, Anand Saggar, †††† Maria Kinali ,¶¶¶, the 4C Study Group, Christian Lorenz ,**** Kristina Moeller, |||| Franz Schaefer,§§§§ Aysun K. Bayazit , Stefanie Weber,¶¶¶¶ William G. Newman ,* and Adrian S. Woolf * Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Urofacial syndrome (UFS) is an autosomal recessive congenital disease featuring grimacing grimacing and dysmorphic bladders. and incomplete bladder emptying. Mutations of HPSE2, encoding heparanase 2, a Considering these and previously pub- heparanase 1 inhibitor, occur in UFS, but knowledge about the HPSE2 mutation spec- lished mutations4–7 (Figure 1A), it is clear trum is limited. Here, seven UFS kindreds with HPSE2 mutations are presented, that pathogenic HPSE2 mutations are including one with deleted asparagine 254, suggesting a role for this amino acid, found across the gene’s coding region. which is conserved in vertebrate orthologs. HPSE2 mutations were absent in 23 non- Most (i.e., nonsense or frameshift muta- neurogenic neurogenic bladder probands and, of 439 families with nonsyndromic tions) would cause loss of function, but a vesicoureteric reflux, only one carried a putative pathogenic HPSE2 variant.
    [Show full text]
  • TRIM32 Is an E3 Ubiquitin Ligase for Dysbindin
    Human Molecular Genetics, 2009, Vol. 18, No. 13 2344–2358 doi:10.1093/hmg/ddp167 Advance Access published on April 6, 2009 TRIM32 is an E3 ubiquitin ligase for dysbindin Matthew Locke1,2, Caroline L. Tinsley1, Matthew A. Benson2,{ and Derek J. Blake1,Ã 1Department of Psychological Medicine, Cardiff University, Henry Wellcome Building for Biomedical Research in Wales, Heath Park, Cardiff, CF14 4XN, UK and 2Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK Received December 15, 2008; Revised and Accepted April 2, 2009 Mutations in the gene encoding tripartite motif protein 32 (TRIM32) cause two seemingly diverse diseases: limb-girdle muscular dystrophy type 2H (LGMD2H) or sarcotubular myopathy (STM) and Bardet–Biedl syndrome type 11(BBS11). Although TRIM32 is involved in protein ubiquitination, its substrates and the molecular consequences of disease-causing mutations are poorly understood. In this paper, we show that Downloaded from TRIM32 is a widely expressed ubiquitin ligase that is localized to the Z-line in skeletal muscle. Using the yeast two-hybrid system, we found that TRIM32 binds and ubiquitinates dysbindin, a protein implicated in the genetic aetiology of schizophrenia, augmenting its degradation. Small-interfering RNA-mediated knock-down of TRIM32 in myoblasts resulted in elevated levels of dysbindin. Importantly, the LGMD2H/ STM-associated TRIM32 mutations, D487N and R394H impair ubiquitin ligase activity towards dysbindin http://hmg.oxfordjournals.org/ and were mislocalized in heterologous cells. These mutants were able to self-associate and also co-immuno- precipitated with wild-type TRIM32 in transfected cells. Furthermore, the D487N mutant could bind to both dysbindin and its E2 enzyme but was defective in monoubiquitination.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Mouse Vipas39 Conditional Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Vipas39 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Vipas39 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Vipas39 gene (NCBI Reference Sequence: NM_001142580 ; Ensembl: ENSMUSG00000021038 ) is located on Mouse chromosome 12. 20 exons are identified, with the ATG start codon in exon 2 and the TAA stop codon in exon 20 (Transcript: ENSMUST00000072744). Exon 3 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Vipas39 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-213E8 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a conditional allele activated by an inducible cre exhibit dry and scaly skin, hair loss, and defects in tail tendon collagen I structure. Exon 3 starts from about 6.38% of the coding region. The knockout of Exon 3 will result in frameshift of the gene. The size of intron 2 for 5'-loxP site insertion: 3170 bp, and the size of intron 3 for 3'-loxP site insertion: 1410 bp. The size of effective cKO region: ~603 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 3 4 20 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Vipas39 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • The Role of Primary Cilia in the Crosstalk Between the Ubiquitin–Proteasome System and Autophagy
    cells Review The Role of Primary Cilia in the Crosstalk between the Ubiquitin–Proteasome System and Autophagy Antonia Wiegering, Ulrich Rüther and Christoph Gerhardt * Institute for Animal Developmental and Molecular Biology, Heinrich Heine University, 40225 Düsseldorf, Germany; [email protected] (A.W.); [email protected] (U.R.) * Correspondence: [email protected]; Tel.: +49-(0)211-81-12236 Received: 29 December 2018; Accepted: 11 March 2019; Published: 14 March 2019 Abstract: Protein degradation is a pivotal process for eukaryotic development and homeostasis. The majority of proteins are degraded by the ubiquitin–proteasome system and by autophagy. Recent studies describe a crosstalk between these two main eukaryotic degradation systems which allows for establishing a kind of safety mechanism. If one of these degradation systems is hampered, the other compensates for this defect. The mechanism behind this crosstalk is poorly understood. Novel studies suggest that primary cilia, little cellular protrusions, are involved in the regulation of the crosstalk between the two degradation systems. In this review article, we summarise the current knowledge about the association between cilia, the ubiquitin–proteasome system and autophagy. Keywords: protein aggregation; neurodegenerative diseases; OFD1; BBS4; RPGRIP1L; hedgehog; mTOR; IFT; GLI 1. Introduction Protein aggregates are huge protein accumulations that develop as a consequence of misfolded proteins. The occurrence of protein aggregates is associated with the development of neurodegenerative diseases, such as Huntington’s disease, prion disorders, Alzheimer’s disease and Parkinson’s disease [1–3], demonstrating that the degradation of incorrectly folded proteins is of eminent importance for human health. In addition to the destruction of useless and dangerous proteins (protein quality control), protein degradation is an important process to regulate the cell cycle, to govern transcription and also to control intra- and intercellular signal transduction [4–6].
    [Show full text]
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Mouse Mutants As Models for Congenital Retinal Disorders
    Experimental Eye Research 81 (2005) 503–512 www.elsevier.com/locate/yexer Review Mouse mutants as models for congenital retinal disorders Claudia Dalke*, Jochen Graw GSF-National Research Center for Environment and Health, Institute of Developmental Genetics, D-85764 Neuherberg, Germany Received 1 February 2005; accepted in revised form 1 June 2005 Available online 18 July 2005 Abstract Animal models provide a valuable tool for investigating the genetic basis and the pathophysiology of human diseases, and to evaluate therapeutic treatments. To study congenital retinal disorders, mouse mutants have become the most important model organism. Here we review some mouse models, which are related to hereditary disorders (mostly congenital) including retinitis pigmentosa, Leber’s congenital amaurosis, macular disorders and optic atrophy. q 2005 Elsevier Ltd. All rights reserved. Keywords: animal model; retina; mouse; gene mutation; retinal degeneration 1. Introduction Although mouse models are a good tool to investigate retinal disorders, one should keep in mind that the mouse Mice suffering from hereditary eye defects (and in retina is somehow different from a human retina, particular from retinal degenerations) have been collected particularly with respect to the number and distribution of since decades (Keeler, 1924). They allow the study of the photoreceptor cells. The mouse as a nocturnal animal molecular and histological development of retinal degener- has a retina dominated by rods; in contrast, cones are small ations and to characterize the genetic basis underlying in size and represent only 3–5% of the photoreceptors. Mice retinal dysfunction and degeneration. The recent progress of do not form cone-rich areas like the human fovea.
    [Show full text]
  • Abstracts from the 51St European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 27:870–1041 https://doi.org/10.1038/s41431-019-0408-3 MEETING ABSTRACTS Abstracts from the 51st European Society of Human Genetics Conference: Electronic Posters © European Society of Human Genetics 2019 June 16–19, 2018, Fiera Milano Congressi, Milan Italy Sponsorship: Publication of this supplement was sponsored by the European Society of Human Genetics. All content was reviewed and approved by the ESHG Scientific Programme Committee, which held full responsibility for the abstract selections. Disclosure Information: In order to help readers form their own judgments of potential bias in published abstracts, authors are asked to declare any competing financial interests. Contributions of up to EUR 10 000.- (Ten thousand Euros, or equivalent value in kind) per year per company are considered "Modest". Contributions above EUR 10 000.- per year are considered "Significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal Genetics then compared this data to de novo cases where research based PO studies were completed (N=57) in NY. E-P01.01 Results: MFSIQ (66.4) for familial deletions was Parent of origin in familial 22q11.2 deletions impacts full statistically lower (p = .01) than for de novo deletions scale intelligence quotient scores (N=399, MFSIQ=76.2). MFSIQ for children with mater- nally inherited deletions (63.7) was statistically lower D. E. McGinn1,2, M. Unolt3,4, T. B. Crowley1, B. S. Emanuel1,5, (p = .03) than for paternally inherited deletions (72.0). As E. H. Zackai1,5, E. Moss1, B. Morrow6, B. Nowakowska7,J. compared with the NY cohort where the MFSIQ for Vermeesch8, A.
    [Show full text]
  • Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample
    Eye Disorders Comprehensive Panel Test Code D4306 Test Summary This test analyzes 211 genes that have been associated with ocular disorders. Turn-Around-Time (TAT)* 3 - 5 weeks Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Commercial Insurance Indications for Testing Individuals with an eye disease suspected to be genetic in origin Individuals with a family history of eye disease Individuals suspected to have a syndrome associated with an eye disease Test Description This panel analyzes 211 genes that have been associated with ocular disorders. Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Diseases associated with this panel include microphtalmia, anophthalmia, coloboma, progressive external ophthalmoplegia, optic nerve atrophy, retinal dystrophies, retinitis pigementosa, macular degeneration, flecked-retinal disorders, Usher syndrome, albinsm, Aloprt syndrome, Bardet Biedl syndrome, pulmonary fibrosis, and Hermansky-Pudlak
    [Show full text]